Summary
Molbio Diagnostics shares have surged nearly 30% in two sessions, extending their post-listing gains to about 80% from the IPO price. This rally follows the company's strong Q1 FY27 performance, which saw it return to a profit of ₹58.75 crore from a loss in the previous year.